Female Sexual Interest
& Arousal Disorder
Understanding FSIAD — What It Is, What Causes It, and What Helps
Changes in sexual interest or arousal are common across a woman's life — and when these changes cause personal distress, they deserve clinical attention. Effective, evidence-based treatment exists.
"Low sexual desire is not a diagnosis. Distressing low sexual desire is. The presence of personal distress is what makes FSIAD a clinical condition — not simply a variation in libido. You decide whether this is a problem worth addressing."
What is FSIAD — and what it is not
Female Sexual Interest/Arousal Disorder (FSIAD) is the DSM-5 term that replaced two older diagnoses — Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Arousal Disorder. It describes a persistent or recurrent pattern of reduced or absent interest in sexual activity, reduced sexual thoughts or fantasies, reduced initiation or responsiveness, and/or reduced physical arousal or sensation — when these changes cause personal distress lasting at least six months.
Distress is required for diagnosis. A natural decline in sexual interest over time — particularly with aging — is not FSIAD. The DSM-5 explicitly requires clinicians to account for the normative changes in sexual response that occur throughout a woman's life before applying this diagnosis. What matters most is whether the change is causing you distress.
Fluctuations in sexual interest are a normal part of female experience — influenced by sleep, stress, relationship factors, body image, the postpartum period, breastfeeding, substance use, medications, and hormonal changes. New-onset symptoms, even in younger women, may also signal an undiagnosed medical or hormonal condition worth investigating.
FSIAD across the female life course
Sexual interest and arousal change throughout a woman's life, with different drivers at different ages. Understanding what phase you are in can help clarify what may be contributing to your experience.
Arousal dysfunction affects approximately 3–9% of women in this age group. Psychosocial factors predominate — relationship discord, stress, depression, anxiety, body image concerns, and medication effects are the primary contributors.
SSRIs and oral contraceptives are notably common medication-related causes. The postpartum period — including breastfeeding and recovery from childbirth — is a significant contributor for many women in this group.
This is the highest-risk period for clinically significant FSIAD. In one prospective study, sexual complaints increased from 42% to 88% over an 8-year span during the menopausal transition.
Declining estradiol, vasomotor symptoms, sleep disruption, mood changes, and emerging vulvovaginal changes compound existing psychosocial stressors. Both biological and relational factors deserve attention in this group.
Low desire continues to increase with age — but personal distress about it tends to decline, so clinically diagnosable FSIAD actually decreases in prevalence after menopause. Genitourinary syndrome of menopause becomes the dominant contributor to arousal and discomfort-related changes.
Notably, orgasmic capacity is generally maintained with aging, though it may require more direct stimulation than in earlier years.
What can contribute to FSIAD
FSIAD is rarely caused by a single factor. ACOG, the DSM-5, and major clinical guidelines recommend a biopsychosocial assessment — evaluation of biological, psychological, relational, and contextual factors — because effective treatment depends on understanding which are most relevant for each individual.
Psychological Factors
Depression, anxiety, body image concerns, perfectionism, self-dislike, history of sexual abuse or intimate partner violence, and psychological sequelae of gynecologic or breast cancer treatment.
Medications
SSRIs and SNRIs are among the most common medication-related causes. Antihypertensives, antihistamines, hormonal contraceptives, and cardiac medications are also recognized contributors.
Hormonal & Endocrine Conditions
Estrogen insufficiency (menopause, hypothalamic amenorrhea, hyperprolactinemia, antiestrogen therapy), diabetes, premature ovarian failure, PCOS, adrenal insufficiency, and thyroid disorders.
Relationship & Contextual Factors
Relationship discord, communication difficulties, emotional disconnection, chronic stress, sedentary lifestyle, sleep disruption, substance use, the postpartum period, and cultural or religious factors.
Medical Conditions
Diabetes, hypertension, neurologic disease, genitourinary syndrome of menopause, chronic pain, pelvic organ prolapse, urinary incontinence, cancer and cancer treatment effects.
Attitudinal & Cultural Factors
Negative sexual attitudes, religious or cultural beliefs creating conflict around sexuality, performance anxiety, and perfectionism — all formally recognized in the DSM-5 biopsychosocial assessment framework.
The Bidirectional Relationship Between FSIAD and Depression
Depression and FSIAD are independently and bidirectionally associated — depression can cause FSIAD, and FSIAD can worsen depressive symptoms. This relationship persists even after controlling for relationship quality, social support, and SSRI use. Anhedonic depression specifically predicts diminished sexual desire, which is why treating underlying depression is frequently a central part of FSIAD care. Both often need to be addressed together.
Conditions that frequently co-occur with FSIAD
FSIAD rarely exists in isolation. The following conditions are identified by the DSM-5 and ACOG as commonly co-occurring — meaning they may contribute to, result from, or exist alongside FSIAD and should be assessed as part of a comprehensive evaluation.
Identifying and treating co-occurring conditions is often the most effective path to improving sexual function — rather than treating FSIAD as an isolated symptom.
What the evidence shows actually helps
Effective treatment for FSIAD is highly individualized. The most appropriate approach depends on what is driving symptoms — which is why a thorough assessment comes first. The following is educational and describes the landscape of evidence-based options, not a treatment plan for any individual.
ACOG, the NEJM, and the DSM-5 all recommend psychosocial interventions as a primary component of FSIAD treatment. A 2025 systematic review confirmed that mindfulness-based CBT significantly improved desire, arousal, and orgasm scores — and reduced distress. No studies have directly compared CBT to pharmacotherapy; both are effective options.
The following have evidence in premenopausal women. All carry specific indications, limitations, and side effect profiles requiring individual clinical discussion.
Sildenafil should not be used for FSIAD outside clinical trials. Systemic DHEA is not effective and is not recommended. (ACOG)
Hormonal treatment options for postmenopausal women are guided by whether genitourinary syndrome of menopause is a contributing factor.
A 2024 NEJM review highlighted targeted physical therapies alongside psychological treatment — particularly relevant when physical components contribute to arousal difficulties.
The most important question is whether this is causing you distress
Sexual interest naturally fluctuates throughout a woman's life — shaped by relationship stage, stress, hormones, sleep, medications, life events, and more. None of these fluctuations are failures. FSIAD is a clinical condition only when the pattern is persistent, lasting at least six months, and causing personal distress. If it is affecting your quality of life, your relationships, or your sense of self — it is worth bringing to a clinician. That is the threshold that matters, and it is yours to define.
You deserve care that takes this seriously
Sexual health is part of overall health. If changes in sexual interest or arousal are affecting your wellbeing, a comprehensive evaluation — conducted with sensitivity and without judgment — can help identify what is contributing and what options may help.
Insurance: Currently accepting Tricare West. Additional plans coming soon. Cash-pay welcome — superbill provided upon request.
Telehealth · Arizona · English & Polish · New patients typically seen within 1–3 days
Begin care with clarity and intention
Whether you are navigating something new or looking for more thoughtful long-term support, MedStart Psychiatry offers a personalized approach designed around you — not the diagnosis alone.
Insurance: We currently accept Tricare West. Additional plans are coming soon. Cash-pay patients are welcome — a superbill can be provided for potential out-of-network reimbursement.
New patients welcome · Appointments often available within 1–3 days · Telehealth · Arizona
Ready to take the next step?
New patients welcome. Appointments often available within 1–3 days. Accepting Tricare West — additional insurance coming soon.
Insurance: Tricare West accepted · Cash-pay & superbill available